Relay Therapeutics stockholders elect directors and approve auditor at 2025 annual meeting

Relay Therapeutics, Inc.

Alexis Borisy elected class II director with 80.7M votes for, 43.0M withheld.
Mark Murcko elected class II director with 79.5M votes for, 44.2M withheld.
Non-binding advisory vote on executive compensation approved: 69.7M for, 53.9M against.
Ratification of Ernst & Young as auditor for FY2025 passed with 142.2M votes for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.